Ventripoint Diagnostics Ltd. Closes Second and Final Tranche of Private Placement

Toronto, Ontario — November 11, 2026 — Leads & Copy — Ventripoint Diagnostics Ltd. has successfully closed the second and final tranche of its non-brokered private placement, increasing the total amount raised through the offering. The company announced the closing of this final tranche, which follows the first tranche that closed on September 8, 2026.

The offering, priced at $0.10 per unit, saw the issuance of an additional 2,224,250 units in the second and final tranche. This brings the aggregate number of units issued to 4,024,250, raising a total of $402,425 for the Corporation. Each unit consists of one common share and one common share purchase warrant. These warrants allow holders to purchase an additional common share at $0.14 for a period of 24 months from the closing date. Ventripoint reserves the right to accelerate the expiry of the warrants if its common shares trade at $0.30 for 10 consecutive days.

Proceeds from the offering will be allocated to commercialization efforts, further development of Ventripoint's core diagnostic technology platform, and general working capital. The offering involved a related party transaction, as insiders subscribed for 460,000 units under the same terms as arm's length subscribers. Ventripoint is utilizing exemptions from valuation and minority shareholder approval requirements under MI 61-101, citing that the corporation is not listed on a specified market and the fair market value of insider participation does not exceed 25% of the corporation's market capitalization.

All securities issued under the offering are subject to a hold period of four months plus one day from the closing date. Final approval from the TSX Venture Exchange is still pending. The securities have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption.

Ventripoint Diagnostics Ltd. is recognized as a leader in applying artificial intelligence to echocardiography. The company's VMS+ products utilize proprietary knowledge-based reconstruction technology, delivering cardiac measurements comparable to MRI. This technology offers an accessible, gold-standard alternative for cardiologists, enhancing patient management and care. The VMS+ platform is compatible with all ultrasound systems from any vendor and holds regulatory market approvals in the U.S., Europe, and Canada.

Source: Ventripoint Diagnostics Ltd.